A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer.

导出 OA

翻译打印收藏纠错

第一作者： John F R,Robertson

第一单位： Division of Breast Surgery, The University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK. John.Robertson@nottingham.ac.uk.

作者： John F R,Robertson ^[1] ; Zefei,Jiang ^[2] ; Angelo,Di Leo ^[3] ; Shinji,Ohno ^[4] ; Kathleen I,Pritchard ^[5] ; Matthew,Ellis ^[6] ; Ian,Bradbury ^[7] ; Christine,Campbell ^[7]

作者单位： Division of Breast Surgery, The University of Nottingham, Nottingham City Hospital, Hucknall Road, Nottingham, NG5 1PB, UK. John.Robertson@nottingham.ac.uk. ^[1] Department of Breast Cancer, Affiliated Hospital of Academy of Military Medical Sciences, No. 8 Dongda Street, Fengtai District, Beijing, 100071, China. ^[2] "Sandro Pitigliani" Medical Oncology Department, Hospital of Prato, Azienda USL Toscana Centro, Piazza Dell'ospedale 2, 59100, Prato, Italy. ^[3] Breast Oncology Center, Cancer Institute Hospital, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. ^[4] Sunnybrook Odette Cancer Centre and the University of Toronto, 2075 Bayview Ave, Toronto, ON, M4N 3M5, Canada. ^[5] Lester and Sue Smith Breast Center, Baylor College of Medicine, 6620 S Main St #1350, Houston, TX, 77030, USA. ^[6] Frontier Science, Grampian View, Kincraig, Kingussie, PH21 1NA, UK. ^[7]

关键词 Advanced breast cancer Clinical benefit rate Fulvestrant Hormone receptor-positive Meta-analysis